An inhibitor (RO-3306) of CDK1 significantly reduced cellular viability (Supplementary Fig. 6c) and proliferation (Supplementary Fig. 6d) for HCC cell lines, including Hep3B, SMMC-7721, Huh-7 and CSQT-2, suggesting that CDK1 could be a target for HCC treatment. This evidence concerns the gene CDK1 and hepatocellular carcinoma.